Table 1.
Patient characteristics
| Characteristics | |
|---|---|
| Median age in years (range) | 71 (57–83) |
| Median KPS in % (range) | 100 (70–100) |
| Median iPSA in ng/mL (range) | 7.9 (3.3–25.4) |
| Median DIL volume in cm3 (range) | 1.4 (0.4–6.6) |
| Gleason score | |
| 6 | 5 (21.7%) |
| 7 | 13 (56.5%) |
| 8–10 | 5 (21.7%) |
| TNM stage | |
| cT1a-c | 21 (91.3%) |
| cT2a-c | 2 (8.7%) |
| D’Amico risk group | |
| Low-risk | 5 (21.7%) |
| Intermediate-risk | 11 (47.8%) |
| High-risk | 7 (30.4%) |
| Index lesion sector distribution | |
| Anterior fibromuscular stroma | 8/23 (34.8%) |
| Anterior TZ | 6/23 (26.1%) |
| Posterior TZ | 5/23 (21.7%%) |
| Anterior PZ | 2/23 (8.7%) |
| Posterior medial PZ | 8/23 (34.8%) |
| Posterior lateral PZ | 11/23 (47.8%) |
| Central zone | 0/23 (0.0%) |
KPS Karnofsky Performance Status, iPSA initial prostate-specific antigen, DIL dominant intraprostatic lesion, TZ transition zone, PZ peripheral zone